about
Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.Ovarian cancer immunotherapy: opportunities, progresses and challengesA dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients.Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responsesImmune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Immunotherapy for ovarian cancer: what's next?The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Immunotherapeutic approaches to ovarian cancer treatment.A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.Immunotherapy in ovarian cancer.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineExpression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcomeTherapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerIntraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment.Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature.Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer.Targeted attack: mechanisms by which ovarian cancers suppress the immune system.VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.Development of anti-human mesothelin-targeted chimeric antigen receptor (CAR) messenger RNA (mRNA)-transfected peripheral blood lymphocytes (CARMA-hMeso) for ovarian cancer therapy.
P2860
Q33552702-25E527B2-39AE-49E4-BCE4-AD4D0A8F7FD9Q33702218-FC253F9E-B9D5-471B-B21D-9F6559248E95Q33724878-36D1FD0A-3007-4BD2-813D-DF1D2C758FF2Q33733534-EAD24BCB-E61A-4383-A7E4-2977C08CB6F2Q33784707-45DD5BCA-D3D2-4F75-A145-77D7205798B2Q34451999-824BCEB2-3FCC-4956-9C98-A81F20FEA712Q34557233-48DADC84-F197-405C-B8FD-CD7052B20DA2Q34743514-04AFA014-CC16-49B9-9914-A95479934B78Q35058213-4F2BFFE0-887C-41D4-BE2E-289826345660Q35213535-51FC771A-D521-4891-BA7A-236794059761Q35627284-ECA97B50-F41B-4DB7-BD06-D759FF06914BQ36226627-A526DFF3-8468-4516-9D51-5E173CA5AD34Q36631249-E3B760B6-E4C6-4CE7-A4A3-659D78AC4CC4Q36958112-F9DFF671-4FD9-4B5F-B221-B4961BD010C1Q37177987-C27D2603-707D-456E-AA74-C3101D6DB194Q37196532-162578FF-7697-45CC-9F7B-3195F707C4D3Q37224420-096DB2BD-DD67-49ED-8F7E-FF3A219B7976Q37308690-68CC6754-FA2F-423E-8CB5-C7FC07EE9143Q37365673-AD2FBB01-8AB4-424C-A274-A9A5DE2A7B33Q37369523-29F8D782-3AB8-4087-8B05-2B23575BA080Q37455627-86DF5110-C6FE-473D-9734-6805D844B822Q37696286-29F5CED9-6E7B-4427-8684-6922134DDDE6Q37709136-94EC8C51-F6D2-49DE-9FD1-B04277D0343DQ37851520-6C3F4C18-3727-4AC5-8880-2D507441BC6EQ39525496-3BA0F925-B1ED-4904-BA46-7BA8E2B6EBE0Q40370693-DDAE246C-8B5D-44F8-97B7-D8DA4795FCCDQ41723681-6EC1DEF8-ACE9-4F14-AAC0-EB78FF18BF5BQ41738853-511CCC0F-5C74-4A26-8774-4B4B988AB4D9Q50025535-9D41DD70-0340-4573-8232-0B9F62D57BCD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunotherapy opportunities in ovarian cancer.
@en
Immunotherapy opportunities in ovarian cancer.
@nl
type
label
Immunotherapy opportunities in ovarian cancer.
@en
Immunotherapy opportunities in ovarian cancer.
@nl
prefLabel
Immunotherapy opportunities in ovarian cancer.
@en
Immunotherapy opportunities in ovarian cancer.
@nl
P2093
P2860
P356
P1476
Immunotherapy opportunities in ovarian cancer
@en
P2093
Carl H June
Christina S Chu
Sarah H Kim
P2860
P304
P356
10.1586/14737140.8.2.243
P577
2008-02-01T00:00:00Z